Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk (NVO) stock in focus as the company wins FDA accelerated nod for weight loss therapy Wegovy against the liver ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1drug Wegovy (semaglutide), as the US Food and Drug ...

The shot was cleared for the disease known as MASH, or metabolic-associated steatohepatitis, in adults with moderate to ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Plainsboro: Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first and ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form ...

Three years after President Joe Biden signed the Inflation Reduction Act, the Trump administration has significantly reduced ...

PLAINSBORO, NJ, USA I August 15, 2025 I Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...